KYC is one time exercise with a SEBI registered intermediary while dealing in securities markets (Broker/ DP/ Mutual Fund etc.). | No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.   |   Prevent unauthorized transactions in your account – Update your mobile numbers / email ids with your stock brokers. Receive information of your transactions directly from exchange on your mobile / email at the EOD | Filing Complaint on SCORES - QUICK & EASY a) Register on SCORES b) Mandatory details for filing complaints on SCORE - Name, PAN, Email, Address and Mob. no. c) Benefits - speedy redressal & Effective communication   |   BSE Prices delayed by 5 minutes... << Prices as on Jan 05, 2026 >>  ABB India 5165.85  [ -0.60% ]  ACC 1771  [ 1.27% ]  Ambuja Cements 571.2  [ 1.06% ]  Asian Paints Ltd. 2814.5  [ 1.52% ]  Axis Bank Ltd. 1285.85  [ 1.45% ]  Bajaj Auto 9498.95  [ -0.02% ]  Bank of Baroda 306.75  [ 0.56% ]  Bharti Airtel 2104.5  [ -0.10% ]  Bharat Heavy Ele 300.1  [ 0.22% ]  Bharat Petroleum 377.95  [ -0.90% ]  Britannia Ind. 6038.95  [ 0.96% ]  Cipla 1519.3  [ 0.55% ]  Coal India 427.45  [ -0.11% ]  Colgate Palm 2091  [ 0.08% ]  Dabur India 521.25  [ -0.20% ]  DLF Ltd. 711.5  [ 1.93% ]  Dr. Reddy's Labs 1248.75  [ -0.53% ]  GAIL (India) 173.05  [ -1.34% ]  Grasim Inds. 2849.1  [ -0.33% ]  HCL Technologies 1607.1  [ -2.00% ]  HDFC Bank 977.7  [ -2.35% ]  Hero MotoCorp 5986.95  [ 0.95% ]  Hindustan Unilever 2383.75  [ 1.53% ]  Hindalco Indus. 931.6  [ 0.63% ]  ICICI Bank 1371.45  [ 1.23% ]  Indian Hotels Co 744.6  [ -0.50% ]  IndusInd Bank 899.5  [ -0.33% ]  Infosys L 1606.4  [ -2.09% ]  ITC Ltd. 349.7  [ -0.13% ]  Jindal Steel 1080.75  [ 0.06% ]  Kotak Mahindra Bank 2190.9  [ -0.19% ]  L&T 4148.85  [ -0.34% ]  Lupin Ltd. 2078.2  [ -1.31% ]  Mahi. & Mahi 3791.55  [ -0.27% ]  Maruti Suzuki India 17154.1  [ 1.14% ]  MTNL 36.67  [ -0.33% ]  Nestle India 1314.2  [ 2.70% ]  NIIT Ltd. 91.27  [ -1.54% ]  NMDC Ltd. 83.88  [ -0.73% ]  NTPC 350.5  [ -0.43% ]  ONGC 238  [ -1.45% ]  Punj. NationlBak 125.05  [ -0.28% ]  Power Grid Corpo 271.65  [ 0.22% ]  Reliance Inds. 1577.45  [ -0.94% ]  SBI 1005.35  [ 0.60% ]  Vedanta 615.6  [ -0.22% ]  Shipping Corpn. 229.15  [ -2.51% ]  Sun Pharma. 1730.15  [ 0.05% ]  Tata Chemicals 746.35  [ -1.17% ]  Tata Consumer Produc 1183  [ 1.09% ]  Tata Motors Passenge 373.5  [ 0.86% ]  Tata Steel 185.7  [ 1.56% ]  Tata Power Co. 388.85  [ -1.06% ]  Tata Consultancy 3214.7  [ -1.09% ]  Tech Mahindra 1595.8  [ -1.04% ]  UltraTech Cement 12081.65  [ 1.57% ]  United Spirits 1375.55  [ -0.42% ]  Wipro 263.35  [ -2.15% ]  Zee Entertainment En 91.19  [ 0.11% ]  
  • Share Prices
  • Tools
  • News
  • Company Details
  • Financial Data
  • Results
  • Key Financial Ratios
  • Reports
  • Corporate Announcements
  • Equity History

    • Company Information

    Indian Indices
    • Loading....

    Global Indices
    • Loading....

    Forex
    • Loading....

    INDOCO REMEDIES LTD.

    05 January 2026 | 12:00

    Industry >> Pharmaceuticals

    Select Another Company

    ISIN No INE873D01024 BSE Code / NSE Code 532612 / INDOCO Book Value (Rs.) 106.21 Face Value 2.00
    Bookclosure 04/09/2025 52Week High 350 EPS 0.00 P/E 0.00
    Market Cap. 2099.65 Cr. 52Week Low 190 P/BV / Div Yield (%) 2.14 / 0.09 Market Lot 1.00
    Security Type Other

    History of Company

    The company history sections lists out major chronological events that happened to the company.
    In 1945, a Goan entrepreneur Mr. Govind Ramnath Kare, who was in the business of wholesale and retail trade of pharmaceuticals, started a firm which he named Indo Continental Trading Company. The principal business of this firm was to import pharmaceutical formulations from Europe and distribute them in Western India. However in 1947, after India became independent, the new Government in its bid to encourage indigenous manufacturing of medicines banned import of several formulations. Mr. G.R. Kare instead of being discouraged, decided to venture into manufacturing of pharmaceuticals. Accordingly, on 23rd August 1947, a week after India's independence, a new Company was founded with the intent to manufacture and sell pharmaceutical formulations. Thus Indo Continental Trading Company became Indoco Remedies Limited.

    The manufacturing operations were started in a small house in Thane near Mumbai. However in this early period, the Company suffered a severe set-back. After Indian independence, the Portuguese Government in Goa sealed the border between Goa and India and Mr. Kare was unable to travel to Mumbai very often. In 1963, two years after Goa's independence, Mr. Suresh Kare, son of Mr. G.R. Kare came to Mumbai and took over as Managing Director of the then sick unit. Under the stewardship of Mr. Suresh Kare, Indoco never looked back. From a meager turnover of Rs. 1 Million and a total employee strength of around 50 in 1969, the Company has grown by leaps and bounds. Indoco now has an estimated turnover of Rs. 1.81 Billion for the year 2003-04 and is over 1750 employees strong.

    2005

    -Indoco Remedies enters into an Agency Agreement with SRU

    2006

    - Indoco Remedies mulls to enter US mkt.

    - Indoco Remedies secures US FDA approvals.

    - Board has proposed a dividend of 62.5%.

    2007

    - Mr. J. B. Salian has been appointed the Secretary of the Company.

    - Board has proposed a dividend of 65% .

    2008

    - Board has recommended a dividend of Rs 5.00 per share.

    - IDMA Quality Excellence Awards 2008 - The Sterile Facility at Goa Plant II received the Gold Award and the Solid Dosage Forms and Externals Facility at Goa Plant I received the Silver Award.

    - First shipment of Diclofenac Ophthalmic solution shipped to USA against an approved ANDA.

    2009

    - Board has decided to declare a final dividend of Rs 2.00 per equity share.

    - UK-MHRA approval for the Solid Oral Dosage forms at Baddi Plant.

    - Successfully faced Slovenia audit for the Sterile Facility at Goa Plant II for the Injections Area.

    2010

    - The Company has signed an agreement with Aspen Pharmacare, South Africa for supply of ophthalmic products.

    - Board has recommended a payment of divided of Rs. 7.00 per equity share.

    - Indoco Remedies teams up with ASPEN, South Africa by licensing out intellectual property (dossiers) for marketing its products in emerging markets covering 30 countries, including SA, Brazil, Mexico, Venezuela, Russia & Australia.

    2011

    - Board has recommended a dividend of Rs. 8/- per equity share.

    - Indoco received the Silver Quality Excellence Award for Sterile Manufacturing Facility in Goa and Solid Dosages Facility in Baddi (Himachal\Pradesh) at IDMA's Golden Jubilee celebrations.

    2012

    - Indoco Remed - Enters into a strategic business alliance with DSM Pharmaceutical Products (DPP) NV.

    - Mr. Sunil Joshi has been appointed as Company Secretary & Compliance Officer of the Company.

    - Indoco announced the signing of an agreement with DSM, a _ 9 billion Company, for commercial cooperation for Active Pharmaceutical Ingredients (APIs). Indoco and DSM have formed a strategic alliance, wherein DSM shall be marketing and selling the APIs manufactured by INDOCO.

    -Company has splits its Face value of Shares from Rs 10 to Rs 2

    -Indoco Remedies has given the Bonus in the Ratio of 1:2

    2013

    -Indoco Remedies Ltd. has received the approval from United States Food & Drug Administration (USFDA) to manufacture and market GLIMEPIRIDE 1mg, 2mg & 4mg tablets.

    -Indoco Remedia Ltd. has recommended payment of dividend of Rs.1.10 per equity share on the face value of Rs. 2/- each i.e. 55% for financial year 2012-13.

    2014

    -US-FDA approves Sterile (Plant II) and Solid Dosages (Plant III) facilities in Goa.

    -IDMA Best Patent Award for Tazarotene & Adapalene.

    -Indoco Remedies Ltd. has Certificate of Good Manufacturing Practice (GMP) Compliance of a Manufacturer.

    2015 - Indoco wins IDMA Patent Appreciation Award for Betaxolol - Indoco acquires Piramal's Clinical Research Division

    2016 - Indoco acquires Manufacturing plant at Baddi - Indoco Honoured with the IDMA Best Patent Award for Three International Patents - Indoco honoured with the 'Best Patent Award' by PHARMEXCIL in the Bulk Drugs / API category

    2017 -Indoco receives the Express Pharma Export Excellence Award 2017 -Indoco receives UKMHRA approval for solid dosages Plant I in Goa -Indoco receives the IDMA Best Patent Award for four API Process Patents -Indoco receives patent grant for Linezolid & Brinzolamide (FDFs) from United States Patent and Trademark Office (USPTO)

    2018 -Indoco commissions For New API manufacturing facility at Patalganga -Indoco's Goa Plant II & III clears USFDA inspection -Indoco's API manufacturing facilities at Patalganga and Rabale successfully clear USFDA inspection -Indoco's API Patalganga site receives Renewed Accreditation Certificate from The Pharmaceuticals and Medical Devices Agency (PMDA), Japan -Indoco receives the IDMA Best Indian Patent Award for five API Process Patents -Indoco's Goa plant III receives EU GMP certification

    2019 -Indoco successfully completes UK-MHRA inspection at Goa Plant II -Indoco gets European Patent Grant for unique process of Brinzolamide Eye Drops -Indoco wins the IDMA Formulations Patent Award 2017-18 for 2 International and 1 Indian patent -Indoco's new solid dosages facility at Baddi receives UK-MHRA approval -Indoco's Sterile Manufacturing Facility (Plant II) Clears USFDA Inspection

    2020 -Indoco wins major tenders in Germany for Allopurinol Tablets -Indoco receives USFDA approval for Apixaban Tablets 2.5 mg & 5 mg -Indoco awarded with the IDMA Formulations Best Patent Award 2018-19 for 2 formulation patents Diclofenac & Quetiapine -Indoco receives USFDA approval for Succinylcholine Chloride Injection USP -Indoco receives USFDA approval for Olanzapine Tablets

    2021 -Indoco announces the launch of Brinzolamide Ophthalmic Suspension 1% in the US market by Teva Pharmaceuticals

    2022 -Indoco Remedies to acquire stake in Kanakal Wind Energy. -Indoco Remedies receives USFDA approval for Lacosamide Injection USP. -Indoco Remedies receives USFDA approval for Lacosamide Tablets.

    2023 -Indoco Remedies receives tentative ANDA approval from USFDA for Canagliflozin Tablets. -Indoco acquires 85 % equity stake in US based FPP Holding Company, LLC. -Indoco receives EIR for its manufacturing facility in Goa (Plant I).

    2024 -Indoco enters into a strategic distribution partnership with Clarity Pharma, UK. -Indoco Remedies receives final ANDA approval from USFDA for Varenicline Tablets, 0.5 mg and 1 mg -Indoco Remedies receives final ANDA approval from USFDA for Pregabalin capsules. -Indoco Remedies receives tentative ANDA approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets. -USFDA successfully completes inspection at Indoco's API Kilo Lab manufacturing facility and IAS division without any observations.

    Way2Wealth Brokers Private Limited - CIN U67120KA2000PTC027628 Stock Broking: SEBI Regn No.: INZ000178638 | Exchange Membership ID: NSE: 11502, BSE: 3117, MSEI:51000, MCX: 56730 Depository Participant: SEBI Regn No. IN-DP-472-2020 | CDSL ID: 12062900 & 12031500, NSDL ID: IN303077 | Research Analyst: SEBI Regn No. INH200008705 | PMS: SEBI Regn No.INP000000829 | Register with AMFI ARN: 77558 (Date of Initial registration - 8th Dec 2009, Date of expiry - 24th Jan 2027) | PFRDA: POP226012019

    Way2Wealth Commodities Private Limited - CIN U51229KA2006PTC039880 Stock Broking: SEBI Regn No.: INZ000049130 | Exchange Membership ID: NCDEX : 00908

    Copyrights @ 2014 © Way2Wealth Brokers Pvt. Ltd. All rights reserved

    Designed, developed and content provided by  Dion

    Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances.